SS
MREO

SBI Securities’s Mereo BioPharma MREO Stock Holding History

SBI Securities’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36 Hold
114
– – ﹤0.01% 3742
2026
Q1 		$38 Buy
+114
New +$49 ﹤0.01% 3630

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SBI Securities's MREO Position: Q2 2026 in Review

SBI Securities held its Mereo BioPharma (MREO) position steady in Q2 2026 at 114 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #3742.

SBI Securities first reported a position in MREO in Q1 2026 and has held it in 2 quarters since. The position peaked at $38 in Q1 2026. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

  • SBI Securities held 114 shares of Mereo BioPharma worth $36 as of Q2 2026.
  • SBI Securities left its Mereo BioPharma share count unchanged in Q2 2026.
  • Mereo BioPharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3742 holding.
  • SBI Securities first reported a position in Mereo BioPharma in Q1 2026 and has held it in 2 quarters since.
  • SBI Securities's Mereo BioPharma position peaked at $38 in Q1 2026.
  • 61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.